Abstract
Introduction: Congenital adrenal hyperplasia (CAH) is characterized by a deficiency of 21α-hydroxylase causing a deficiency of cortisol and aldosterone and overproduction of 17-hydroxyprogesterone. The classic and non-classical forms of the disease present with signs of precocious puberty (PP) and accelerated body and bone growth. Elevated basal and stimulated 17-hydroxyprogesterone and genetic testing are crucial for confirming a definitive diagnosis.
Aim: To determine the significance of elevated basal 17-hydroxyprogesterone in children with signs of precocious puberty in the final diagnosis of Congenital Adrenal Hyperplasia.
Material and methods: A prospective study was conducted at the University Children's Clinic and the Institute of Molecular Genetics and Genetic Engineering in Belgrade from 2019 to 2024. The study involved 64 subjects of both sexes, aged up to 18 years, with precocious puberty, accelerated bone and body growth, elevated basal 17-hydroxyprogesterone, who were divided into two groups based on the presence/absence of pathogenic variants in the CYP21A2 gene. The anthropometric measures, skeletal maturation and hormone levels were compared between those two groups.
Results: The research includes 64 subjects, divided into two groups, with confirmed CAH (30 subjects) and with PP as the control group (34 subjects). A statistically significant difference was shown in basal (p=0.000000807) and stimulated 17-hydroxyprogesterone (p= 0.0125), cortisol (p= 0.0148) and androstenedione (p= 0.014) in homozygous carriers of pathogenic variants in the CYP21A2 gene.
Conclusion: Clinical and laboratory parameters such as precocious puberty and 17-hydroxyprogesterone may be significant hints to consider a carrier mutation for congenital adrenal hyperplasia.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.